Despite improved survival of patients with systemic autoimmune disease, severe disease can still be lethal. Autologous human stem cell transplantation is an exciting therapeutic option for patients with organ or life threatening disease. The initial open pilot study must be safety oriented. Data collection will be standardized and centralized. Efforts will be coordinated by a working party from the European League Against Rheumatism and the European group for Blood and Marrow Transplantation.